Every 10-Q that Clene Inc. (CLNN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLNN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLNN filings page.
Clene Inc. reported that it remains a clinical-stage company with limited revenue and continued losses, and disclosed that conditions raise substantial doubt about its ability to continue as a going concern. For the three months ended June 30, 2026, total revenue was $90 thousand, while the net loss widened to $13.4 million from $7.4 million a year earlier, driven largely by $7.5 million of non-cash losses from changes in fair value of warrant and derivative liabilities and interest expense.
For the six months ended June 30, 2026, the net loss was $21.5 million. Cash, cash equivalents and restricted cash increased to $9.7 million at June 30, 2026 from $5.2 million at December 31, 2025, mainly due to $11.7 million of net proceeds from common stock and warrant offerings, while net cash used in operating activities was $7.1 million, modestly lower than the prior-year period. Total assets were $23.0 million and total liabilities $47.8 million, resulting in a stockholders’ deficit of $24.8 million. The company is subject to covenants on its senior secured convertible notes, including maintaining at least $2.0 million of unrestricted cash, and plans to seek additional financing, partnerships, and use of its at-the-market facility.
Clene Inc. reported a net loss of $8.1 million for the quarter ended March 31, 2026, compared with $0.8 million a year earlier. Revenue was minimal at $15,000, down from $81,000, reflecting its early-stage status.
Operating loss improved to $2.1 million from $4.1 million as research and development and general and administrative expenses fell sharply, but large non-cash items, including a $4.6 million loss on the initial issuance of equity and higher warrant-related charges, drove the larger bottom-line loss.
Cash and cash equivalents were $5.9 million as of March 31, 2026, with net cash used in operating activities of $4.5 million in the quarter. Total liabilities of $40.5 million exceeded total assets of $21.7 million, resulting in a stockholders’ deficit of $18.8 million. The company discloses substantial doubt about its ability to continue as a going concern within 12 months without additional financing, despite raising $6.0 million during the quarter and $7.0 million shortly thereafter through registered direct equity offerings.
Clene Inc. reported Q3 2025 results highlighting limited revenue and continued losses. Total revenue was $15 thousand (product $0, royalty $15 thousand). Loss from operations was $5.6 million, and net loss was $8.8 million (basic and diluted EPS $(0.85)).
Cash and cash equivalents were $7.9 million at September 30, 2025, down from $12.2 million at year-end. Net cash used in operating activities for the nine months was $13.7 million. The company reported a stockholders’ deficit of $12.4 million. Management stated that conditions “raise substantial doubt” about the ability to continue as a going concern, including a covenant to maintain at least $2.0 million of unrestricted cash under the 2024 senior secured convertible notes.
To support liquidity, Clene raised $3.3 million via its equity distribution agreement during Q3 and $1.5 million from new senior secured convertible notes, and subsequently generated $1.2 million more from the equity distribution. Shares outstanding were 10,333,980 as of November 10, 2025. Grant funding reduced expenses by $2.3 million (R&D) and $0.1 million (G&A) in the quarter.
Clene Inc. is a clinical-stage pharmaceutical company developing clean-surfaced nanocrystal therapeutics for central nervous system disorders. For the quarter ended June 30, 2025, cash and cash equivalents were $7.3 million (down from $12.2 million at 12/31/2024), total assets were $22.1 million, and total liabilities were $30.7 million, producing a stockholders' deficit of $(8.6) million. Revenue remained minimal at $27 thousand for the quarter and $108 thousand for the six months ended June 30, 2025, while net loss for the six months was $8.17 million (net loss per share, basic and diluted, $0.89).
The company disclosed substantial doubt about its ability to continue as a going concern, citing recurring operating losses, negative operating cash flow of $9.8 million for the six months, and an accumulated deficit of $290.3 million. Material financing and liquidity items include a $45.1 million NIH grant with up to $30.9 million of subawards to Clene (reimbursements recognized; $6.4 million recognized in the six months), equity distribution proceeds of $5.1 million in the six months (plus $1.9 million subsequent to period end), and convertible senior secured notes with covenants requiring at least $2.0 million of unrestricted cash to avoid acceleration. Management is pursuing additional financing and has implemented cost-saving measures, but concluded these plans do not alleviate the substantial doubt about operations beyond one year.